Details of the Drug Combination

General Information of Drug Combination (ID: DC81JE9)

Drug Combination Name
Rifapentine Moxifloxacin
Indication
Disease Entry Status REF
Mycobacterium Tuberculosis Phase 1 [1]
Component Drugs Rifapentine   DMCHV4I Moxifloxacin   DMU8V4S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rifapentine
Disease Entry ICD 11 Status REF
Pulmonary tuberculosis 1B10.Z Approved [2]
Tuberculosis 1B10-1B1Z Approved [3]
Macular degeneration 9B78.3 Investigative [4]
Rifapentine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA-directed RNA polymerase (RNAP) TTHKJLN NOUNIPROTAC Binder [6]
------------------------------------------------------------------------------------
Rifapentine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Rifapentine Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [8]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [9]
Arylacetamide deacetylase (AADAC) OT8VACT2 AAAD_HUMAN Decreases Acetylation [10]
------------------------------------------------------------------------------------
Indication(s) of Moxifloxacin
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [3]
Mycoplasma pneumoniae pneumonia N.A. Approved [5]
Peritonitis N.A. Approved [5]
Pneumonic plague N.A. Approved [5]
Septicemic plague N.A. Approved [5]
Staphylococcal pneumonia N.A. Approved [5]
Staphylococcus aureus infection N.A. Approved [5]
Streptococcal pneumonia N.A. Approved [5]
Tuberculosis 1B10-1B14 Approved [5]
Pneumonia caused by chlamydia N.A. Investigative [5]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [5]
Moxifloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [11]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00460759) Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
2 Rifapentine FDA Label
3 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
4 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
5 Moxifloxacin FDA Label
6 Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7.
7 Inhibitory potential of twenty five anti-tuberculosis drugs on CYP activities in human liver microsomes. Biol Pharm Bull. 2015;38(9):1425-9.
8 Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos. 2006 Oct;34(10):1742-8.
9 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
10 Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol. 2011 Dec 1;82(11):1747-56.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.